Benefits and Drawbacks of Emergency Use Authorizations for COVID Vaccines
The EUA pathway may impede vital scientific progress needed to establish the long term safety and efficacy of investigational COVID-19 vaccines.
FDA
-
Read more: Benefits and Drawbacks of Emergency Use Authorizations for COVID Vaccines -
Read more: Authorize Emergency Vaccines for COVID-19, but Do It Well Authorize Emergency Vaccines for COVID-19, but Do It Well
We can simultaneously get COVID vaccines to those most at risk while minimizing harm to our ability to fully evaluate their safety and efficacy.
-
Read more: Health Care AI in Pandemic Times Health Care AI in Pandemic Times
The rapid deployment of COVID-19 predictive models may have a lasting impact on the oversight of health care AI.
-
Read more: COVID-19 and the FDA Emergency Use Authorization Power COVID-19 and the FDA Emergency Use Authorization Power
This blog post provides an overview of the FDA’s emergency authorization powers and analyzes the extent of their usage in the COVID-19 pandemic.
-
Read more: Why the Government Shouldn’t Pay People to Get Vaccinated Against COVID-19 Why the Government Shouldn’t Pay People to Get Vaccinated Against COVID-19
Paying for vaccination is dubious public health policy likely to backfire in terms of (re)building public trust in vaccines.
-
Read more: Under an EUA, Can Businesses Require Employees and Customers to Get Vaccinated? Under an EUA, Can Businesses Require Employees and Customers to Get Vaccinated?
Can private businesses mandate that employees and customers receive COVID-19 vaccines authorized for emergency use?
-
Read more: What Does the Good News on the Vaccine Front Mean? What Does the Good News on the Vaccine Front Mean?
In the past weeks, three companies in advanced stages of COVID-19 vaccine trials reported good news. What does this mean?
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from October 2020.
-
Read more: Fortifying the US Pharmaceutical Supply Chain Fortifying the US Pharmaceutical Supply Chain
Reducing dependency on any single nation must be a federal priority, but it can be accomplished only with industry stakeholder buy-in.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Selections feature topics ranging from political pressures facing the FDA, to the financial incentive structure for antibiotic development.
